A multi-center study of fidaxomicin use for Clostridium difficile infection

SpringerPlus

Volumn 5, Issue 1, 2016, Pages

  Shah, Dhara N ^a   Chan, Fay S ^a   Kachru, Nandita ^a   Garcia, Krutina P ^a   Balcer, Holly E ^b   Dyer, April P ^c   Emanuel, John E ^d   Jordan, Michelle D ^e   Lusardi, Katherine T ^f   Naymick, Geri ^g   Polisetty, Radhika S ^h   Sieman, Lanny ⁱ   Tyler, Ashley M ^j   Johnson, Michael L ^a   Garey, Kevin W ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b Roper St Francis Healthcare   (United States)

^c Southeastern Health ^*  (United States)

^d OhioHealth   (United States)

^e VIDANT MEDICAL CENTER   (United States)

^f UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

^g St Mary's Hospital Medical Center   (United States)

^h CENTRAL DUPAGE HOSPITAL   (United States)

ⁱ North kansas City Hospital   (United States)

^j Division of Surgical Endocrinology   (United States)

more..

Author keywords

Anaerobe infections; Clinical practice; Pharmacoepidemiology; Real world study; Treatment

Indexed keywords

EID: 84982711501     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/s40064-016-2825-x     Document Type: Article

References (29)

1. Aitken SL, Joseph TB, Shah DN, Lasco TM, Palmer HR, DuPont HL et al (2014) Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS ONE 9(7):e102848. doi:10.1371/journal.pone.0102848
2. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL (2012) Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 55(Suppl 2):S162–S169. doi:10.1093/cid/cis453
3. Bauer MP, Kuijper EJ, van Dissel JT (2009) European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 15(12):1067–1079. doi:10.1111/j.1469-0691.2009.03099.x
4. Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A (2013) Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 57(9):4501–4505. doi:10.1128/AAC.01120-13
5. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31(5):431–455. doi:10.1086/651706
6. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K et al (2012a) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12(4):281–289. doi:10.1016/S1473-3099(11)70374-7
7. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL (2012b) Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 55(Suppl 2):S154–S161. doi:10.1093/cid/cis462
8. Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA et al (2012) Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 55(Suppl 2):S93–S103. doi:10.1093/cid/cis499
9. Debast SB, Bauer MP, Kuijper EJ (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20(Suppl 2):1–26. doi:10.1111/1469-0691.12418
10. Eiland EH 3rd, Sawyer AJ, Massie NL (2015) Fidaxomicin use and clinical outcomes for associated diarrhea. Infect Dis Clin Pract (Baltim MD) 23(1):32–35. doi:10.1097/IPC.0000000000000181
11. Gallagher JC, Reilly JP, Navalkele B, Downham G, Haynes K, Trivedi M (2015) Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother 59(11):7007–7010. doi:10.1128/AAC.00939-15
12. Goldenberg SD, Brown S, Edwards L, Gnanarajah D, Howard P, Jenkins D et al (2016) The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis 35(2):251–259. doi:10.1007/s10096-015-2538-z
13. Kelly CP, LaMont JT (2008) Clostridium difficile—more difficult than ever. N Engl J Med 359(18):1932–1940
14. Kyne L, Hamel MB, Polavaram R, Kelly CP (2002) Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34(3):346–353. doi:10.1086/338260
15. Lawrence SJ, Puzniak LA, Shadel BN, Gillespie KN, Kollef MH, Mundy LM (2007) Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol 28(2):123–130. doi:10.1086/511793
16. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR et al (2015) Burden of Clostridium difficile infection in the United States. N Engl J Med 372(9):825–834. doi:10.1056/NEJMoa1408913
17. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y et al (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364(5):422–431. doi:10.1056/NEJMoa0910812
18. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M et al (2012) Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55(Suppl 2):S132–S142. doi:10.1093/cid/cis338
19. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN (1999) Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 20(1):43–50. doi:10.1086/501553
20. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS et al (2011) Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 53(5):440–447. doi:10.1093/cid/cir404
21. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ (2012) Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 55(Suppl 2):S121–S126. doi:10.1093/cid/cis440
22. Orenstein R (2012) Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing. Clin Infect Dis 55(4):613–614. doi:10.1093/cid/cis495
23. Penziner S, Dubrovskaya Y, Press R, Safdar A (2015) Fidaxomicin therapy in critically ill patients with Clostridium difficile infection. Antimicrob Agents Chemother 59(3):1776–1781. doi:10.1128/AAC.04268-14
24. Safavi KC, Li SX, Dharmarajan K, Venkatesh AK, Strait KM, Lin H et al (2014) Hospital variation in the use of noninvasive cardiac imaging and its association with downstream testing, interventions, and outcomes. JAMA Intern Med 174(4):546–553. doi:10.1001/jamainternmed.2013.14407
25. Shah DN, Bhatt NS, Welch JK, Koo HL, Garey KW (2013) Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect 83(4):294–299. doi:10.1016/j.jhin.2012.12.011
26. Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Heguy A, Nault V, Valiquette L (2016) Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis 62(5):574–580. doi:10.1093/cid/civ958
27. Soriano MM, Danziger LH, Gerding DN, Johnson S (2014) Novel fidaxomicin treatment regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies. Open Forum Infect Dis 1(2):ofu069. doi:10.1093/ofid/ofu069
28. Vargo CA, Bauer KA, Mangino JE, Johnston JE, Goff DA (2014) An antimicrobial stewardship program’s real-world experience with fidaxomicin for treatment of Clostridium difficile infection: a case series. Pharmacotherapy 34(9):901–909. doi:10.1002/phar.1451
29. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45(3):302–307. doi:10.1086/519265